Downloads: 6 | Views: 249 | Weekly Hits: ⮙1 | Monthly Hits: ⮙1

Research Paper | Diabetology | India | Volume 12 Issue 8, August 2023 | Popularity: 5.4 / 10

Rate This Article!      

A Comparative Retrospective Study of Vildagliptin 100mg SR OD and Sitagliptin 100 mg in Subjects with Type 2 Diabetes Mellitus

Dr. K. Vamsi Krishna, Dr Sanjeet Kumar Jaiswal, Dr Subodh Jain, Dr Syed Haroon Iqubal, Dr. Sona Warrier, Dr. Ashish Prasad, Dr. Ashish Birla, Mr. Vinod More, Dr. Ravindra Mote

Abstract: Diabetes mellitus is a chronic metabolic disorder characterized by insufficient insulin secretion from ? - cells of pancreatic islet leads to increased blood glucose level and cause damage to the cardiovascular system, kidneys, eyes, and nerves. Dipeptidyl peptidase 4 (DPP - 4) inhibitors are the drugs that inhibit degradations of incretin hormones which enhance insulin secretion. Vildagliptin and Sitagliptin are oral DDP - 4 inhibitors that aid to control blood glucose levels in type 2 diabetes mellitus. An assessment of efficacy was performed by measuring the post - treatment glycosylated hemoglobin (HbA1c) levels. This was a Single - centre, Retrospective, Comparative Clinical Study that recruited a total number of 340 subjects fulfilling study criteria. Subjects who were on stable doses of metformin and with HbA1c values between ?8% to <11% were included. The study consists of two treatment groups, Vildagliptin 100 mg SR Tablets (Treatment A) and Sitagliptin 100 mg Tablets (Treatment B), and HbA1c, Fasting blood glucose (FBG), and post - prandial blood glucose (PPBG) levels from baseline to week 16 were compared. The study endpoints were to estimate the mean change in HbA1c, FBG, and PPBG from baseline to week 16 (Visit 3). Statistical data analysis was done using SAS 9.4. Descriptive statistical analysis was expressed as the means ? standard deviation. A total of 340 subjects suffering from T2DM were included and analyzed; of which 174 were in the Vildagliptin group and 166 were in the Sitagliptin group. After 16 weeks of treatment with study drugs, it was found that a significant reduction was observed in HbA1c, FBG, and PPBG levels in the Vildagliptin group as compared to the Sitagliptin group. Results of this retrospective study revealed that Vildagliptin and Sitagliptin showed comparable efficacy profiles for controlling the levels of various glucose parameters.

Keywords: Retrospective, Type 2 Diabetes mellitus, Vildagliptin, Sitagliptin, Dipeptidyl peptidase - 4 inhibitor

Edition: Volume 12 Issue 8, August 2023

Pages: 2350 - 2355

DOI: https://www.doi.org/10.21275/SR23822112319

Make Sure to Disable the Pop-Up Blocker of Web Browser

Click to Cite this Article

Similar Articles